Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25939514 | 0.88 | TP53 (0.55) | TP53TSHRSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL25939640 | 0.88 | TP53 (0.55) | TP53TSHRSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL3282634 | 0.88 | TP53 (0.55) | TP53TSHRSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL12437005 | 0.83 | TP53 (0.63) | TP53TSHRSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL29497130 | 0.82 | TSHR (0.78) | TSHRSMN1; SMN2L3MBTL1CYP2C19MEN1 | |
| SCHEMBL3377958 | 0.81 | TP53 (0.61) | TP53TSHRSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL4682503 | 0.81 | TP53 (0.61) | TP53TSHRSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL5310151 | 0.80 | TP53 (0.56) | TP53TSHRSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL23581751 | 0.80 | TSHR (0.58) | TP53TSHRSMN1; SMN2CYP2C19MEN1 | |
| SCHEMBL7906419 | 0.80 | TSHR (0.58) | TP53TSHRSMN1; SMN2MAPTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107235867-A | It is used as the aryl sultam derivative of RORc conditioning agents | 弗·哈夫曼-拉罗切有限公司 | 2017-10-10 | — | — | CN | claimed |
| CN-104470917-B | Aryl sultam derivatives as RORc modulators | 弗·哈夫曼-拉罗切有限公司 | 2017-08-04 | — | — | CN | claimed |
| EP-2872504-B1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | claimed |
| EP-2872504-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. Hoffmann-La Roche AG (CH) | 2015-05-20 | — | — | EP | claimed |
| CN-104470917-A | Aryl sultam derivatives as RORc modulators | HOFFMANN LA ROCHE | 2015-03-25 | — | — | CN | claimed |
| WO-2014009447-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | claimed |
| US-7601726-B2 | Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-13 | — | — | US | claimed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | claimed |
| EP-1761542-B1 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | claimed |
| CN-101001860-A | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (CH) | 2007-07-18 | — | — | CN | claimed |
| WO-2007058482-A1 | NOVEL INHIBITORS OF PROTEIN KINASE | LG LIFE SCIENCES, LTD. (KR) | 2007-05-24 | — | — | WO | claimed |
| EP-1761542-A2 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | claimed |
| WO-2005121145-A2 | OCTAHYDRO-PYRROLO[3,4-C] DERIVATIVES AND THEIR USE AS ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | WO | claimed |
| US-6911453-B2 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-28 | — | — | US | claimed |
| WO-2004113353-A1 | SILICON-COMPRISING AMINOTHIAZOLE DERIVATIVES AS CDK INHIBITORS | AMEDIS PHARMACEUTICALS LTD. (GB) | 2004-12-29 | — | — | WO | claimed |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-03-04 | — | — | US | claimed |
| EP-4522596-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119497712-A | Indane derivatives as MALT1 inhibitors | 希四克斯探索有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
| WO-2000039118-A1 | AROMATIC AMIDES | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | TP53 713/4885TSHR 3750/4885SMN1; SMN2 2505/4885 |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | ABCB11, SLC10A1, PON1 | TP53 1059/4885TSHR 2810/4885SMN1; SMN2 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.